8-K: Oncocyte Announces Successful GraftAssure Beta Launch and Q2 2024 Results, Highlighting Transplant Market Expansion

Oncocyte reports a successful beta launch of its GraftAssure transplant assay and second quarter 2024 financial results, emphasizing a land and expand strategy in the transplant market.

Summary

• Oncocyte has successfully launched its GraftAssure research-use-only assay, designed to detect early signs of organ damage in transplant patients.
• The company's GraftAssure assay was first used outside of an Oncocyte lab at a major US transplant center on July 11, 2024, followed by a center in Southeast Asia.
• Oncocyte's US sales pipeline includes transplant centers representing approximately 25% of US transplant volumes.
• The company is seeing significant interest in GraftAssure in Germany, other European countries, Asia, and the Middle East.
• Oncocyte has a land and expand strategy, aiming to establish its technology at research centers before seeking FDA clearance for clinical use.
• The company aims to have more than 20 transplant centers running GraftAssure tests by the end of 2025, including 15 in the US.
• Each center is estimated to generate an annual high-margin revenue stream of several hundred thousand dollars to $2 million.
• The company anticipates FDA clearance for its IVD product in late 2025 and a MolDX reimbursement decision in early 2026.
• Second quarter 2024 revenue was $104,000, with a gross profit of $50,000.
• Operating expenses were $4.7 million, and the loss from continuing operations was $4.5 million, or $0.36 per share.
• Oncocyte's cash balance at the end of the second quarter was approximately $11.0 million, including $1.7 million in restricted cash.
• The company raised approximately $9.9 million in net proceeds from a private placement in April 2024.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment due to the successful launch of GraftAssure and the strong market interest. However, the company is still in the early stages of commercialization and faces financial challenges, which tempers the overall optimism.

Positives

• The successful beta launch of GraftAssure demonstrates the company's ability to execute its product development strategy.
• The high level of interest in GraftAssure from transplant centers suggests strong market demand.
• The land and expand strategy positions the company for future growth and revenue generation.
• The appointment of a new CFO with a strong track record is a positive step for the company's financial management.
• The company's partnerships with Bio-Rad and other companies validate its technology and market approach.
• The company has a strong intellectual property position with patents granted in the US and EU.
• The company has a streamlined capital structure after the recent capital raise.

Negatives

• The company reported a net loss of $4.5 million for the second quarter of 2024.
• The revenue of $104,000 in the second quarter was relatively low.
• The company is still in the early stages of commercialization and faces risks associated with regulatory approvals and market adoption.
• The company's operating expenses of $4.7 million are significant compared to its revenue.

Risks

• The company faces risks inherent in the development and commercialization of diagnostic tests.
• There is uncertainty in the results of clinical trials and regulatory approvals.
• The company's success depends on its ability to obtain future capital.
• The company needs to maintain its intellectual property rights.
• There are risks associated with strategic transactions and partnerships.
• The company needs to obtain third-party reimbursement for its tests.
• The company's manufacturing partner needs to be able to scale to meet global demand.

Future Outlook

Oncocyte is focused on expanding the commercialization of its transplant tests, achieving FDA clearance for its IVD product, and increasing the number of transplant centers using GraftAssure. The company anticipates a MolDX reimbursement decision in early 2026 and expects the Increasing Organ Transplant Access Model to increase demand for dd-cfDNA testing.

Management Comments

• We are thrilled to report that we have successfully launched GraftAssureTM.
• The level of interest and enthusiasm in the market is exceeding our expectations.
• We believe that we are at an inflection point in commercializing our molecular diagnostic tests.
• We are pleased to be delivering upon our commitments and are thrilled with our market momentum.
• Our mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes.

Industry Context

The announcement highlights Oncocyte's efforts to capitalize on the growing market for transplant diagnostics, particularly in the area of early detection of organ damage. The company's focus on dd-cfDNA testing aligns with industry trends towards non-invasive monitoring solutions. The partnership with Bio-Rad leverages a global distribution network, which is a common strategy for diagnostic companies.

Comparison to Industry Standards

• The company's GraftAssure test uses ddPCR technology, which provides results in 4-8 hours, compared to 30 hours for competitors using NGS technology, such as CareDx with AlloSure.
• Oncocyte's approach of a kitted test for research use before IVD approval is similar to strategies used by other diagnostic companies to establish market presence.
• The company's focus on a land and expand strategy is a common approach in the diagnostics industry, similar to companies like Exact Sciences with Cologuard.
• The company's partnership with Bio-Rad for distribution is similar to other diagnostic companies that leverage established distribution networks, such as Roche with its various diagnostic products.
• The company's claim of being more profitable than larger diagnostic companies due to its low infrastructure costs is a bold statement that will need to be proven over time, but is a common goal for smaller companies in the space.

Management Changes

Stakeholder Impact

• Shareholders may benefit from the company's growth and potential for future revenue generation.
• Employees may benefit from the company's growth and expansion.
• Customers (transplant centers) will have access to a new diagnostic tool.
• Patients may benefit from improved transplant monitoring and outcomes.
• Suppliers may benefit from increased demand for their products and services.

Next Steps

• Oncocyte will continue to roll out its GraftAssure research product to transplant centers throughout 2024 and 2025.
• The company will submit a Q-Sub to the FDA and hopes to receive feedback by the end of 2024.
• Oncocyte aims to achieve FDA IVD clearance in late 2025.
• The company will continue to develop new use cases for its technology.

Key Dates

Keywords

GraftAssure, transplant, dd-cfDNA, diagnostics, IVD, FDA, Bio-Rad, VitaGraft, molecular diagnostics, reimbursement